- Home
- NRGV vs MDXH Comparison
NRGV vs MDXH Comparison
Compare NRGV & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- MDXH
- Stock Information
- Founded
- NRGV 2017
- MDXH 2003
- Country
- NRGV United States
- MDXH Belgium
- Employees
- NRGV N/A
- MDXH N/A
- Industry
- NRGV Industrial Machinery/Components
- MDXH
- Sector
- NRGV Miscellaneous
- MDXH
- Exchange
- NRGV Nasdaq
- MDXH Nasdaq
- Market Cap
- NRGV 102.3M
- MDXH 84.6M
- IPO Year
- NRGV N/A
- MDXH 2021
- Fundamental
- Price
- NRGV $0.86
- MDXH $2.18
- Analyst Decision
- NRGV Buy
- MDXH Buy
- Analyst Count
- NRGV 3
- MDXH 1
- Target Price
- NRGV $1.58
- MDXH $6.00
- AVG Volume (30 Days)
- NRGV 2.1M
- MDXH 63.5K
- Earning Date
- NRGV 08-05-2025
- MDXH 08-20-2025
- Dividend Yield
- NRGV N/A
- MDXH N/A
- EPS Growth
- NRGV N/A
- MDXH N/A
- EPS
- NRGV N/A
- MDXH N/A
- Revenue
- NRGV $46,974,000.00
- MDXH $94,507,000.00
- Revenue This Year
- NRGV $362.17
- MDXH $23.51
- Revenue Next Year
- NRGV $48.19
- MDXH $17.68
- P/E Ratio
- NRGV N/A
- MDXH N/A
- Revenue Growth
- NRGV N/A
- MDXH 25.46
- 52 Week Low
- NRGV $0.60
- MDXH $1.35
- 52 Week High
- NRGV $2.70
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- NRGV 52.80
- MDXH 56.42
- Support Level
- NRGV $0.65
- MDXH $2.12
- Resistance Level
- NRGV $0.74
- MDXH $2.32
- Average True Range (ATR)
- NRGV 0.07
- MDXH 0.12
- MACD
- NRGV 0.00
- MDXH 0.00
- Stochastic Oscillator
- NRGV 73.80
- MDXH 73.33
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.